

# Scott A North

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9301416/publications.pdf>

Version: 2024-02-01

117  
papers

12,966  
citations

76326  
40  
h-index

24258  
110  
g-index

117  
all docs

117  
docs citations

117  
times ranked

12028  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abiraterone and Increased Survival in Metastatic Prostate Cancer. New England Journal of Medicine, 2011, 364, 1995-2005.	27.0	3,736
2	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factorâ€“Targeted Agents: Results From a Large, Multicenter Study. Journal of Clinical Oncology, 2009, 27, 5794-5799.	1.6	1,751
3	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology, The, 2012, 13, 983-992.	10.7	1,182
4	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 121-131.	27.0	982
5	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. European Urology, 2017, 72, 544-554.	1.9	638
6	The Impact of Cytorreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy. Journal of Urology, 2011, 185, 60-66.	0.4	322
7	A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormoneâ€“refractory prostate cancer. Cancer, 2007, 110, 1959-1966.	4.1	276
8	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncology, The, 2012, 13, 1210-1217.	10.7	254
9	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2015, 67, 241-249.	1.9	235
10	Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 4247-4254.	1.6	221
11	Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). European Urology, 2014, 66, 815-825.	1.9	221
12	Metastatic nonâ€“clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer, 2013, 119, 2999-3006.	4.1	189
13	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clinical Cancer Research, 2017, 23, 6487-6497.	7.0	121
14	Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c. Clinical Cancer Research, 2011, 17, 5765-5773.	7.0	120
15	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncology, The, 2012, 13, 927-935.	10.7	112
16	Associations between Exercise and Quality of Life in Bladder Cancer Survivors: A Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 984-990.	2.5	86
17	The 2014 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC). Canadian Urological Association Journal, 2015, 9, 90.	0.6	82
18	Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castrationâ€“resistant prostate cancer. Journal of Clinical Pharmacology, 2015, 55, 1406-1414.	2.0	78

#	ARTICLE	IF	CITATIONS
19	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e79-e85.	1.9	78
20	Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. <i>Expert Review of Vaccines</i> , 2005, 4, 249-257.	4.4	76
21	Exercise programming and counseling preferences in bladder cancer survivors: a population-based study. <i>Journal of Cancer Survivorship</i> , 2007, 1, 27-34.	2.9	75
22	Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy. <i>Urology</i> , 2010, 76, 430-434.	1.0	75
23	Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trial. <i>Cancer</i> , 2017, 123, 4057-4065.	4.1	74
24	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3181-3188.	1.6	73
25	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. <i>European Urology</i> , 2014, 65, 1086-1092.	1.9	71
26	Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors. <i>British Journal of Cancer</i> , 2018, 118, 1313-1321.	6.4	70
27	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. <i>European Urology</i> , 2014, 65, 723-730.	1.9	69
28	Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. <i>European Urology</i> , 2021, 80, 693-700.	1.9	65
29	Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 311-315.	1.9	64
30	Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2021, 18, 104-114.	3.8	57
31	A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer†. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 143-149.	1.6	55
32	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , 2016, 10, 46.	0.6	55
33	Correlates of physical activity in a population-based sample of kidney cancer survivors: an application of the theory of planned behavior. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2012, 9, 96.	4.6	52
34	A prospective study of the determinants of exercise in bladder cancer survivors using the Theory of Planned Behavior. <i>Supportive Care in Cancer</i> , 2009, 17, 171-179.	2.2	50
35	Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. <i>European Urology</i> , 2015, 68, 570-577.	1.9	50
36	A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naïve castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2012, 30, 1652-1659.	2.6	47

#	ARTICLE	IF	CITATIONS
37	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Targeted Oncology, 2013, 8, 203-209.	3.6	47
38	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2020, 78, 834-844.	1.9	47
39	Associations Between Physical Activity and Quality of Life in a Population-Based Sample of Kidney Cancer Survivors. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 859-868.	2.5	41
40	Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Canadian Urological Association Journal, 2013, 7, 44.	0.6	41
41	A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Canadian Urological Association Journal, 2013, 3, 281.	0.6	39
42	Physical activity preferences in a population-based sample of kidney cancer survivors. Supportive Care in Cancer, 2012, 20, 1709-1717.	2.2	37
43	Randomized Controlled Trial of a Behavior Change Intervention to Increase Physical Activity and Quality of Life in Prostate Cancer Survivors. Annals of Behavioral Medicine, 2013, 46, 382-393.	2.9	34
44	Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology, 2006, 68, 565-569.	1.0	33
45	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Canadian Urological Association Journal, 2017, 11, 112.	0.6	32
46	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2019, 2, 643-648.	5.4	31
47	L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opinion on Biological Therapy, 2007, 7, 1723-1730.	3.1	30
48	Quality indicators in the management of bladder cancer: A modified Delphi study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 328-334.	1.6	29
49	A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. Clinical Genitourinary Cancer, 2019, 17, 201-208.e1.	1.9	29
50	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 3.e17-3.e27.	1.6	29
51	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq1 1 0.784314 rgBT /Over 837-846.	1.6	29
52	Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2022, 40, LBA5004-LBA5004.	1.6	29
53	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 2021, 80, 275-279.	1.9	28
54	Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer, 2016, 122, 411-419.	4.1	27

#	ARTICLE	IF	CITATIONS
55	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 354-358.	1.9	26
56	Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada. <i>Canadian Urological Association Journal</i> , 2019, 14, E57-E64.	0.6	26
57	Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study. <i>Thrombosis Research</i> , 2003, 112, 59-64.	1.7	25
58	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e127-e131.	1.9	25
59	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. <i>European Journal of Cancer</i> , 2019, 108, 69-77.	2.8	25
60	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2019, 13, 307-314.	0.6	21
61	Social-ecological correlates of physical activity in kidney cancer survivors. <i>Journal of Cancer Survivorship</i> , 2016, 10, 164-175.	2.9	20
62	A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. <i>Canadian Urological Association Journal</i> , 2013, 3, 369.	0.6	19
63	The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study. <i>Bladder Cancer</i> , 2018, 4, 185-194.	0.4	19
64	Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. <i>Canadian Urological Association Journal</i> , 2013, 7, 312.	0.6	18
65	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. <i>Canadian Urological Association Journal</i> , 2015, 9, 164.	0.6	18
66	A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. <i>Oncotarget</i> , 2018, 9, 8155-8164.	1.8	18
67	A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Intrapleural Instillation of Methylprednisolone Acetate in the Management of Malignant Pleural Effusion. <i>Chest</i> , 2003, 123, 822-827.	0.8	15
68	CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update. <i>Canadian Urological Association Journal</i> , 2013, 7, 231.	0.6	15
69	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	1.6	15
70	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 403-410.e2.	1.9	14
71	Associations between sitting time and quality of life in a population-based sample of kidney cancer survivors. <i>Mental Health and Physical Activity</i> , 2013, 6, 16-23.	1.8	13
72	Feasibility and Preliminary Efficacy of Adding Behavioral Counseling to Supervised Physical Activity in Kidney Cancer Survivors. <i>Cancer Nursing</i> , 2014, 37, E8-E22.	1.5	13

#	ARTICLE	IF	CITATIONS
73	The Canadian Urology Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. <i>BJU International</i> , 2008, 102, 551-555.	2.5	12
74	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. <i>Canadian Urological Association Journal</i> , 2014, 8, 309.	0.6	12
75	Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 331-340.	1.9	12
76	Intermittent LHRH Therapy in the Management of Castrate-resistant Prostate Cancer (CRPCa). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 601-605.	1.3	11
77	Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience. <i>Canadian Urological Association Journal</i> , 2014, 8, 287.	0.6	11
78	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97.	0.6	11
79	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 150-155.	1.9	10
80	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <i>Canadian Urological Association Journal</i> , 2019, 13, 343-54.	0.6	10
81	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537.	2.5	10
82	2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) (full-text). <i>Canadian Urological Association Journal</i> , 2020, 15, E81-9.	0.6	10
83	First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 335-340.	1.9	9
84	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2018, 12, E281-97.	0.6	9
85	Outcome of advanced stage low grade follicular lymphomas in a population-based retrospective cohort. , 1999, 85, 1361-1368.		8
86	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e233-e242.	1.9	8
87	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2019, 13, 318-327.	0.6	8
88	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. <i>Canadian Urological Association Journal</i> , 2020, 14, E373-E382.	0.6	8
89	The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review. <i>Oncologist</i> , 2021, 26, e1381-e1394.	3.7	8
90	Management of Advanced Kidney Cancer – Canadian Kidney Cancer Forum Consensus Update. <i>Canadian Urological Association Journal</i> , 2013, 7, 238.	0.6	7



#	ARTICLE	IF	CITATIONS
91	A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer. Canadian Urological Association Journal, 2014, 8, 583.	0.6	7
92	Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder?. Canadian Urological Association Journal, 2013, 2, 222.	0.6	6
93	Expression of Nucleoside Transporters and Deoxycytidine Kinase Proteins in Muscle Invasive Urothelial Carcinoma of the Bladder: Correlation with Pathological Response to Neoadjuvant Platinum/Gemcitabine Combination Chemotherapy. Journal of Urology, 2014, 191, 35-39.	0.4	6
94	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. Canadian Urological Association Journal, 2017, 11, 310-320.	0.6	6
95	Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio. Clinical Genitourinary Cancer, 2018, 16, e637-e644.	1.9	6
96	The role of the built environment in a randomized controlled trial to increase physical activity among men with prostate cancer: the PROMOTE trial. Supportive Care in Cancer, 2017, 25, 2993-2996.	2.2	5
97	Changes in motivational outcomes following a supervised physical activity program with behavioral counseling in kidney cancer survivors: a pilot study. Psycho-Oncology, 2015, 24, 1204-1207.	2.3	4
98	Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). Investigational New Drugs, 2016, 34, 771-776.	2.6	4
99	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World Journal of Urology, 2021, 39, 4345-4354.	2.2	4
100	A phase II trial of weekly i.v. KW-2170 in advanced castrate-resistant prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 292-297.	1.1	3
101	Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer. Journal of Oncology Pharmacy Practice, 2019, 25, 1293-1300.	0.9	3
102	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2019, 14, E115-E125.	0.6	3
103	Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 559-566.	1.3	3
104	Patterns of cost-related medication underuse among Canadian adults with cancer: a cross-sectional study using survey data. CMAJ Open, 2021, 9, E474-E481.	2.4	3
105	Small cell carcinoma of the genitourinary tract: A 10-year single institution experience.. Journal of Clinical Oncology, 2012, 30, 312-312.	1.6	2
106	Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. Journal of Medical Economics, 2022, 25, 583-590.	2.1	2
107	The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210948.	3.2	2
108	Perioperative chemotherapy for muscle invasive bladder cancer. Current Opinion in Supportive and Palliative Care, 2015, 9, 249-254.	1.3	1

#	ARTICLE	IF	CITATIONS
109	High fat mass associates with occurrence of targeted therapy-induced left ventricular ejection fraction reduction in patients with renal cell carcinoma. Clinical Nutrition, 2018, 37, 1070-1072.	5.0	1
110	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. Bladder Cancer, 2020, 6, 363-392.	0.4	1
111	Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.. Journal of Clinical Oncology, 2012, 30, 451-451.	1.6	1
112	Prise en charge du cancer du rein de stade avancé : Mise à jour 2013 des lignes directrices consensuelles du Forum canadien sur le cancer du rein. Canadian Urological Association Journal, 2013, 7, .	0.6	0
113	Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC). Journal of Cancer Education, 2019, 34, 14-18.	1.3	0
114	The management of malignant pleural effusions in breast cancer. , 2005, , 129-140.		0
115	Assessing the utility of cabazitaxel in mCRPC. Canadian Urological Association Journal, 2016, 10, 111.	0.6	0
116	Socioeconomic disparities in the prevalence of comorbid chronic conditions among Canadian adults with cancer. Acta Oncologica, 2022, 61, 294-301.	1.8	0
117	Dr. North's rebuttal. Canadian Urological Association Journal, 2008, 2, 228.	0.6	0